DexCom, Inc. Share Price and Company Fundamentals
Last traded: Yesterday at 8:00 PM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Key Metrics
PE ratio
85.30
PB ratio
23.25
Dividend yield
0.00%
Beta
1.22
Market cap
-
Enterprise value
-
Company profile
| Industry / Sector | Medical Devices / Healthcare |
|---|---|
| Full time employees | 9500 |
| Website | https://www.dexcom.com |
| Mailing address | 6340 Sequence Drive San Diego CA 92121 United States |
| Phone / Fax | 858 200 0200 / |
Dividends
Dividend yield
0.00%
Dividend amount
$0.00
Payout ratio
0.00%
DexCom, Inc. paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.DXCM dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
DXCM's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
Company Executives
As of May 2024, following are the company executives and directors listed on DexCom, Inc..
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Kevin Ronald Sayer | Executive Chairman, CEO & President | 65 | 3.23M |
| Mr. Jereme M. Sylvain | Executive VP, CFO & Chief Accounting Officer | 43 | 1.13M |
| Mr. Jacob Steven Leach | Executive VP & COO | 45 | 1.29M |
| Mr. Michael Jon Brown | Executive VP & Chief Legal Officer | 53 | 1.22M |
| Ms. Teri Lawver | Executive VP & Chief Commercial Officer | 56 | 1.41M |
| Mr. Girish Naganathan | Executive VP & CTO | 46 | 423.92k |
| Mr. Sean Christensen | Director of Corporate Affairs & Head of Investor Relations | ||
| Mr. Matthew Dolan | Executive Vice President of Strategy, Corporate Development & Dexcom Labs | 42 | |
| Ms. Leverne Marsh | Executive Vice President of Marketing | ||
| Ms. Sadie M. Stern | Executive VP & Chief Human Resources Officer | 48 |
Profitability and management effectiveness
Profit margin
16.82%
Operating margin
10.98%
Return on assets
6.79%
Return on equity
28.54%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of DexCom, Inc. is and its enterprise value is .
The DXCM's stocks Beta value is 1.22 making it 22% more volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
DexCom, Inc. (NASDAQ:DXCM) Frequently Asked Questions
1. What is DexCom, Inc.'s Stock Symbol?
DexCom, Inc. trades on NASDAQ under the ticker symbol "DXCM".
2. What is DexCom, Inc.'s stock price today?
One share of DXCM stock can currently be purchased for approximately $131.36.
3. How can I contact DexCom, Inc.?
DexCom, Inc.'s mailing address is 6340 Sequence Drive San Diego CA 92121 United States. The company can be reached via phone at 858 200 0200.
4. What is DexCom, Inc.'s official website?
The official website of DexCom, Inc. is https://www.dexcom.com.